StockNews.com assumed coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note published on Sunday. The brokerage issued a hold rating on the stock. Separately, HC Wainwright restated a buy rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, August 15th. Read Our […]
StockNews.com initiated coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note published on Saturday morning. The brokerage issued a hold rating on the stock. Separately, HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, August 15th. […]
Several brokerages have updated their recommendations and price targets on shares of Galectin Therapeutics (NASDAQ: GALT) in the last few weeks: 8/19/2023 – Galectin Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 8/15/2023 – Galectin Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They […]
StockNews.com began coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research report released on Saturday morning. The brokerage issued a hold rating on the stock. Separately, HC Wainwright restated a buy rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, August 15th. Read […]
HC Wainwright reissued their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a report released on Tuesday morning, Benzinga reports. The firm currently has a $11.00 price target on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ Q3 2023 earnings at ($0.16) EPS, Q4 2023 earnings at ($0.16) EPS, […]